Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Petrelli

Showing results (21-30 of 348) with videos related to

Pageof 35
Sort By:
Clinical Breast Cancer|January 2, 2013
A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancerFausto Petrelli, Sandro Barni
Clinical Genitourinary Cancer|October 8, 2013
Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapiesFausto Petrelli, Sandro Barni
Translational Lung Cancer Research|March 26, 2015
Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLCFausto Petrelli, Sandro Barni
Thrombosis Research|April 3, 2021
Reply to the letter to the editor 'Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review' by Frere et alFausto Petrelli, Cinzia Solinas
Annals of Palliative Medicine|April 6, 2015
The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?Fausto Petrelli, Sandro Barni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Rethinking Optimal Therapy for Operable Pancreatic Cancer in the CASSANDRA EraFausto Petrelli, Lorenzo Dottorini
Breast Cancer Research and Treatment|November 24, 2021
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx studySandro Barni, Francesco Cognetti, Fausto Petrelli
Expert Review of Anticancer Therapy|November 5, 2015
Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agentsAndrea Coinu, Fausto Petrelli, Sandro Barni
JAMA Oncology|June 28, 2017
Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals-ReplyGianluca Tomasello, Fausto Petrelli, Sandro Barni
The Lancet. Oncology|April 8, 2015
Adjuvant chemotherapy for rectal cancerFausto Petrelli, Andrea Coinu, Sandro Barni
Pageof 35

Showing results (21-30 of 348) with videos related to

Sort By:
Pageof 35
Clinical Breast Cancer|January 2, 2013
A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancerFausto Petrelli, Sandro Barni
Clinical Genitourinary Cancer|October 8, 2013
Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapiesFausto Petrelli, Sandro Barni
Translational Lung Cancer Research|March 26, 2015
Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLCFausto Petrelli, Sandro Barni
Thrombosis Research|April 3, 2021
Reply to the letter to the editor 'Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review' by Frere et alFausto Petrelli, Cinzia Solinas
Annals of Palliative Medicine|April 6, 2015
The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?Fausto Petrelli, Sandro Barni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Rethinking Optimal Therapy for Operable Pancreatic Cancer in the CASSANDRA EraFausto Petrelli, Lorenzo Dottorini
Breast Cancer Research and Treatment|November 24, 2021
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx studySandro Barni, Francesco Cognetti, Fausto Petrelli
Expert Review of Anticancer Therapy|November 5, 2015
Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agentsAndrea Coinu, Fausto Petrelli, Sandro Barni
JAMA Oncology|June 28, 2017
Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals-ReplyGianluca Tomasello, Fausto Petrelli, Sandro Barni
The Lancet. Oncology|April 8, 2015
Adjuvant chemotherapy for rectal cancerFausto Petrelli, Andrea Coinu, Sandro Barni
Pageof 35